- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03643549
Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17) (BORTEM-17)
Bortezomib Sensitization of Recurrent Grade-4 Glioma With Unmethylated MGMT Promoter to Temozolomide Phase 1B/II Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients harbouring tumours with functional O6 methylguanine DNA methyltransferase (MGMT) DNA repair enzyme efficiently repair the DNA damage inflicted by Temozolomide and gain limited benefit from this chemotherapy. Bortezomib depletes the MGMT enzyme, restoring the tumour´s susceptibility to Temozolomide, if the chemotherapy is administered in the precise schedule when the MGMT enzyme is depleted. Additionally, Bortezomib inhibits the growth of tumour cells by blocking autophagy flux. Temozolomide causes genotoxic stress in cancer cells that in turn respond by inducing protective processes such as autophagy. If both autophagy and MGMT DNA repair enzyme are blocked a priori, the efficacy of Temozolomide will be enhanced. Thus, pre-treating the tumour with Bortezomib prior to administration of Temozolomide leads to DNA repair enzyme depletion and blockade of autophagy-induced survival signals. The combined effect will sensitize the tumour to therapy, improve chemotherapy efficacy and prolong patient survival outcomes.
Hypothesis: Pretreatment with Bortezomib administered prior to Temozolomide will sensitize recurrent GBM with unmethylated MGMT promoter to standard TMZ in palliative setting.
Objective:
- Assessment of safety and tolerability of Bortezomib administered with Temozolomide.
- Determining the optimal dose of TMZ, when administered as combination therapy
- Estimate the progression free survival (PFS) and overall survival (OS) of patients with recurrent or progressed glioblastoma after pre-treatment with Bortezomib prior to combination with Temozolomide.
Key secondary objectives
- Tumour response to the therapy assessed by RANO and NANO criteria
- Determine physiological, molecular and biochemical changes in blood and tumour tissue that correlate with treatment responses.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Dorota Goplen, MD, PhD
- Phone Number: +47 55974019
- Email: dgop@helse-bergen.no
Study Contact Backup
- Name: Martha E Chekenya, PhD, Dr. Philos
- Phone Number: +47 55586380
- Email: martha.enger@uib.no
Study Locations
-
-
-
Bergen, Norway, 5021
- Recruiting
- Haukeland University Hospital
-
Contact:
- Dorota Goplen, MD, PhD
- Phone Number: +4755974019
- Email: dgop@helse-bergen.no
-
Contact:
- Jorunn Brekke, MD
- Phone Number: +4755970986
- Email: joub@helse-bergen.no
-
Oslo, Norway, 0424
- Recruiting
- Oslo University Hospital
-
Contact:
- Petter Brandal, MD
- Email: pebra@ous-hf.no
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Life expectancy > 8 weeks
- Histologically confirmed intracranial glioblastoma (GBM), with MGMT unmethylated promoter
- Must submit an unstained paraffin block and/ or cryopreserved tumour tissue from surgical procedure
- Radiologically (MRI) confirmed tumour relapse/progression ≥ 12 weeks since completed radiotherapy
- Measurable recurrent tumor
- Tumor not available for radio-surgery
- If previously treated with gammaknife, at least one evaluable lesion outside the irradiated area is required, unless the time after the radiosurgery is 12 weeks or more
- Written informed consent for study participation and tumour, blood sample collection obtained before performance of any study related procedure.
- Karnofsky performance status ≥ 70
- WBC ≥ 3,000/mm^3
- ANC ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Hemoglobin ≥ 10 g/dL (transfusion allowed)
- Bilirubin < 2.5 times upper limit of normal (ULN)
- serum aspartate aminotransferase (AST) < 2.5 times ULN
- Estimated GFR ≥ 60 mL/minute
- Serum sodium > 130 mmol/L
- Serum potassium level within normal limit
- Stable or reduced doses of corticosteroids for at least 1 week prior to enrolment
- Negative pregnancy test no longer than 14 days prior to enrollment
- Fertile patients and female partners with child bearing potential of male patients must use adequate contraception
- Patients on EIAED must be transitioned to non-EAIED for ≥ 2 weeks
- Unfractionated and/or low molecular weight heparin allowed
- Patients previously treated with neurosurgery er eligible for the study
Exclusion Criteria:
- Hypersensitivity to Bortezomib, boron, or mannitol
- Any contraindications for use of temozolomide
- Peripheral neuropathy ≥ grade 2
- Previous treatment with bevacizumab or lomustine alone or as a combination therapy for ralapsed glioblastoma (PCV as primary treatment of low grade glioma, before development of glioblastoma, is allowed)
- Myocardial infarction within the past 6 months
- NYHA class III or IV heart failure
- Uncontrolled angina
- Severe uncontrolled ventricular arrhythmias
- Electrocardiographic evidence of acute ischemia or active conduction system abnormalities
- Known heart failure
- Serious medical or psychiatric illness that would interfere with the study participation including, but not limited to, any of the following:
- Ongoing or active infection requiring IV antibiotics
- Psychiatric illness and/or social situations that would limit compliance with study requirements
- Disorders associated with a significant immunocompromised state (e.g., HIV, systemic lupus erythematosus)
- History of stroke within the past 6 months
- Other malignancy within the past 3 years except completely resected basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy (i.e., cervical cancer), or low-risk prostate cancer after curative therapy
- Significant medical illness that, in the investigator's opinion, cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy
- Disease that will obscure toxicity or dangerously alter the drug metabolism
- Viral hepatitis (HBV surface antigen positive) or active hepatitis C infection
- Other investigational drugs must be stopped at least 12 weeks prior to therapy or treatment failure under other experimental therapy must be confirmed before study entry. If progression during other experimental therapy is confirmed, the time interval between previous treatment and BORTEM-17 may be reduced to 4 weeks
- Concurrent inducers of CYP450 3A4 (e.g., enzyme-inducing anti-epileptic drugs [EIAED])
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bortezomib and Temozolomide
Botezomib 1.3 mg/m2 administered IV on days 1, 4, 7, during each 4-week chemotherapy cycle with per oral Temozolomide at three dose levels: 150 mg/m2, 175 mg/m2 and 200mg/m2 5 days/week every 4 weeks starting on day 3.
|
In the Phase IB of the study the following dose escalation of TMZ will be performed: The first cohort of 3 patients will receive 150 mg/m2 of IMP (TMZ) for 5 days q4w.
If one patient in this cohort develops a dose limiting toxicity, another cohort of 3 patients will be treated at the same dose level until 2 or more patients in the group of 3-6 develop DLT.
The patientes will be treated with the maximum recommended starting dose of Temozolomide and Bortezomib established in the IB phase of the study
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bortezomib-Temozolomide Maximum tolerated dose
Time Frame: 6 months
|
En intra- and inter-patient dose escalation period of TMZ administered after Bortezomib
|
6 months
|
Overall survival
Time Frame: 1 year
|
Overall survival at 1 year
|
1 year
|
Progression free survival
Time Frame: 6 months
|
Progression free survival at 6 months
|
6 months
|
Time to progression
Time Frame: 4 years
|
Median time
|
4 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biomarkers of treatment response
Time Frame: 4 years
|
Identification of novel tumor biomarkers by determining physiological, molecular and biochemical changes in blood and tumor tissue that correlate with treatment responses
|
4 years
|
Tumour responses
Time Frame: 4 years
|
Assessed by contrast enhanced MRI according to RANO criteria
|
4 years
|
Clinical response
Time Frame: 4 years
|
Assessment of the neurologic status according to NANO criteria
|
4 years
|
Toxicity assessment
Time Frame: 4 years
|
SAE, all grades hematologic and non hematologic toxicity
|
4 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Dorota Goplen, MD, PhD, Haukeland University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioblastoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Temozolomide
- Bortezomib
Other Study ID Numbers
- 2017/2084
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component | Relapsed GlioblastomaUnited States
-
Juan M Garcia-GomezHospital Universitario 12 de Octubre; Hospital Clínico Universitario de ValenciaRecruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) MutantSpain
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
Northwestern UniversityAgenus Inc.; CarTheraRecruitingGlioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-WildtypeUnited States
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingGlioblastoma | Astrocytoma | Recurrent Glioblastoma | MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-WildtypeUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
Clinical Trials on Bortezomib and Temozolomide Phase IB
-
Immatics Biotechnologies GmbHBristol-Myers SquibbRecruitingCancer | Solid Tumor, Adult | Refractory Cancer | Recurrent CancerGermany
-
Boryung Pharmaceutical Co., LtdActive, not recruitingFollicular Lymphoma | B Cell Lymphoma | Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Peripheral T Cell Lymphoma | Small Lymphocytic LeukemiaKorea, Republic of, United States
-
Immatics Biotechnologies GmbHRecruitingCancer | Solid Tumor, Adult | Refractory Cancer | Recurrent CancerGermany
-
Shanghai Hansoh Biomedical Co., LtdRecruiting
-
Shanghai Hansoh Biomedical Co., LtdRecruitingAdvanced Solid TumorChina
-
CStone PharmaceuticalsBlueprint Medicines CorporationCompletedHepatocellular CarcinomaChina
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...Recruiting
-
Jason J. Luke, MDArray BioPharmaActive, not recruitingMelanoma | Renal Cell Carcinoma | Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell CarcinomaUnited States
-
Butantan InstituteButantan FoundationActive, not recruiting
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedLymphoma | Brain and Central Nervous System Tumors | Unspecified Adult Solid Tumor, Protocol Specific | Metastatic CancerUnited States